CYAD News and Press, Celyad SA From 01/18/21

Median overall survival and median progression free survival from the dose-escalation segment of the trial were 10.6 months and 3.9 months, respectively Tumor burden decrease observed in eight of 15 refractory unresectable mCRC patients, including six of nine patients at the hig...

Celyad Oncology's technology, although still under development, has exciting possibilities, including the simplification of design and development of future therapy candidates, which could make therapies available 'off the shelf'. There is no getting around the fact that CYAD's produc...

MONT-SAINT-GUIBERT, Belgium, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that Marina Udie...

Celyad Oncology (CYAD) has entered into an equity purchase agreement with Chicago-based institutional investor, Lincoln Park Capital Fund ((LPC)). Under the 24-month term Equity Purchase Agreement, LPC will purchase up to $40M ADS, each of which represents one or...

MONT-SAINT-GUIBERT, Belgium, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, to...

MONT-SAINT-GUIBERT, Belgium, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the company...

A Phase 1 Chinese biotech developing CAR-T cell therapies for cancer, Gracell Biotechnologies (GRCL) to raise $150M by offering 8.825M ADSs at a price range of $16 to $18.Underwriters' over-allotment is an additional 1,323,750 ADSs.Net proceeds together with existing cash and cash equiva...

Gracell Biotechnologies has filed to raise $100 million in a U.S. IPO, although the final figure may vary. The firm is developing treatments for various cancers using a CAR-T approach. GRCL has produced very promising Phase 1 trial results for its lead candidate. For further...

Celyad Oncology (CYAD) has dosed the first patient in the expansion cohort of the Phase 1 alloSHRINK trial evaluating CYAD-101, its allogeneic T cell receptor inhibitory molecule-based, non-gene edited CAR T candidate for the treatment of refractory metastatic colorectal cancer. The stud...

Preliminary data from the expansion cohort are expected during first half 2021 MONT-SAINT-GUIBERT, Belgium, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of ch...